Last reviewed · How we verify
Palbociclib plus an aromatase inhibitor
Palbociclib plus an aromatase inhibitor is a Small molecule drug developed by Pfizer. It is currently in Phase 2 development.
At a glance
| Generic name | Palbociclib plus an aromatase inhibitor |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma (PHASE1, PHASE2)
- Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer (PHASE2)
- Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery (PHASE2)
- Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor (PHASE2)
- Swedish Ibrance Registries Insights (SIRI)
- Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
- PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection (PHASE3)
- AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Palbociclib plus an aromatase inhibitor CI brief — competitive landscape report
- Palbociclib plus an aromatase inhibitor updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Palbociclib plus an aromatase inhibitor
What is Palbociclib plus an aromatase inhibitor?
Palbociclib plus an aromatase inhibitor is a Small molecule drug developed by Pfizer.
Who makes Palbociclib plus an aromatase inhibitor?
Palbociclib plus an aromatase inhibitor is developed by Pfizer (see full Pfizer pipeline at /company/pfizer).
What development phase is Palbociclib plus an aromatase inhibitor in?
Palbociclib plus an aromatase inhibitor is in Phase 2.